GRNA | Jotup

GreenLight Announces Completion of Merger with Fall Line Endurance Fund

Retrieved on:

Monday, July 24, 2023

LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced the closing of its previously announced merger with SW MergerCo, Inc. (“Merger Sub”) and SW ParentCo, Inc. (“Parent”), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the “Merger”).

Key Points:

LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced the closing of its previously announced merger with SW MergerCo, Inc. (“Merger Sub”) and SW ParentCo, Inc. (“Parent”), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the “Merger”).
Concurrent with the closing of the Merger, GreenLight completed its previously announced financing of $52.075 million from a syndicate of investors led by Fall Line Capital, LLC (“Fall Line”), of which $15 million had been previously funded in exchange for the issuance of $15 million of unsecured notes.
The merger and concurrent financing positions GreenLight for increased efficiency and nimbleness to adapt to changing market opportunities.
“This merger and financing empowers GreenLight to operate with enhanced efficiency, advancing us closer to our mission of fostering healthy people and planet.” said Zarur.

GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares

Retrieved on:

Thursday, July 20, 2023

Treasury, PBC, Guaranteed, Sub, Tax, SW, Corporate law, GRNA, Mergers and acquisitions, Contribution, Rollover, DGCL, Parent, Holding company, Green-light

As of one minute after 11:59 p.m. (New York City time) on July 19,2023, a total of 18,791,264 shares of GreenLight common stock were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 60.4% of the outstanding shares of GreenLight common stock not otherwise owned by Merger Sub, its affiliates or the Rollover Stockholders.

Key Points:

As of one minute after 11:59 p.m. (New York City time) on July 19,2023, a total of 18,791,264 shares of GreenLight common stock were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 60.4% of the outstanding shares of GreenLight common stock not otherwise owned by Merger Sub, its affiliates or the Rollover Stockholders.
In addition, “Notices of Guaranteed Delivery” have been delivered for 477,399 shares of GreenLight common stock, representing approximately 1.5% of the outstanding shares not otherwise owned by Merger Sub, its affiliates or the Rollover Stockholders.
Merger Sub intends to accept for payment in accordance with the terms of the Offer all shares of GreenLight common stock that were validly tendered and not validly withdrawn as of the expiration of the Offer.
Merger Sub will be merged with and into GreenLight, with GreenLight continuing as the surviving corporation that is wholly owned by the Parent.

ALERT: The M&A Class Action Firm Continues Investigating the Merger – VKIN, GRNA, FRG, AAIC

Retrieved on:

Wednesday, June 7, 2023

Franchise Group, PBC, Rwanda Energy Group, FRG, Empire, Sale, GRNA, AAIC, OTC, Monteverde, NYSE, Security (finance)

GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA ), relating to its proposed sale to Fall Line Capital LLC.

Key Points:

GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA ), relating to its proposed sale to Fall Line Capital LLC.
Under the terms of the agreement, GRNA shareholders are expected to receive $0.30 in cash per share they own.
Under the terms of the agreement, FRG shareholders are expected to receive $30.00 in cash per share they own.
Under the terms of the agreement, AAIC shareholders will receive 0.3619 shares of Ellington and $0.09 in cash per share they own.

Lifshitz Law PLLC Announces Investigations of GRNA, AAIC, EMBK, and REUN

Retrieved on:

Sunday, June 4, 2023

Telephone, GRNA, BioImpacts, AAIC, Advertising, MPM, Hewlett, Intuition, Sale, Online shopping, Security (finance)

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of AAIC and Ellington Financial Inc.

Key Points:

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of AAIC and Ellington Financial Inc.
Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EMBK to Applied Intuition, Inc. for $2.88 per share in cash.
Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of REUN to affiliates of MPM BioImpact for $1.12 per share in cash.
The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.

GREENLIGHT BIOSCIENCES INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of GreenLight Biosciences Holdings, PBC - GRNA

Retrieved on:

Thursday, June 1, 2023

Class Action Lawsuit, Professional Services, Legal, GRNA, Green-light, KSF, PBC, Sale

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of GreenLight Biosciences Holdings, PBC (NasdaqGM: GRNA) to a consortium led by Fall Line Capital, LLC.

Key Points:

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of GreenLight Biosciences Holdings, PBC (NasdaqGM: GRNA) to a consortium led by Fall Line Capital, LLC.
Under the terms of the proposed transaction, shareholders of GreenLight will receive $0.30 in cash for each share of GreenLight that they own.
Please note that the merger is structured as a tender offer, such that time may be of the essence.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

ALERT: The M&A Class Action Firm Continues Investigating the Merger – FRG, GRNA, EMBK, AAIC

Retrieved on:

Wednesday, May 31, 2023

Franchise Group, PBC, Intuition, FRG, Empire, Sale, GRNA, AAIC, Monteverde, NYSE, Security (finance)

Under the terms of the agreement, FRG shareholders are expected to receive $30.00 in cash per share they own.

Key Points:

Under the terms of the agreement, FRG shareholders are expected to receive $30.00 in cash per share they own.
GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA ), relating to its proposed sale to Fall Line Capital LLC.
Under the terms of the agreement, GRNA shareholders are expected to receive $0.30 in cash per share they own.
Under the terms of the agreement, AAIC shareholders will receive 0.3619 shares of Ellington and $0.09 in cash per share they own.

GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction

Retrieved on:

Tuesday, May 30, 2023

LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that the Company has entered into a definitive agreement (the “Merger Agreement”) to be acquired by a group of buyers led by Fall Line Capital, LLC (“Fall Line”) in an all-cash transaction valuing the Company at approximately $45.5 million.

Key Points:

LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that the Company has entered into a definitive agreement (the “Merger Agreement”) to be acquired by a group of buyers led by Fall Line Capital, LLC (“Fall Line”) in an all-cash transaction valuing the Company at approximately $45.5 million.
Subject to customary closing conditions, the Company expects the transaction to close in the third quarter of 2023.
Under the terms of the Merger Agreement, the Company may solicit alternative acquisition proposals from third parties during a 30-day “go-shop” period beginning on the date of the Merger Agreement.
O’Melveny & Myers LLP is serving as legal counsel to Fall Line.

GRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of GreenLight Biosciences Holdings, PBC Is Fair to Shareholders

Retrieved on:

Tuesday, May 30, 2023

Class Action Lawsuit, Professional Services, Legal, GRNA, Green-light, Fraud, Fall line, Advertising, PBC, Sale, Security (finance)

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) to a group of buyers led by Fall Line Capital, LLC for $0.30 per share is fair to GreenLight shareholders.

Key Points:

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) to a group of buyers led by Fall Line Capital, LLC for $0.30 per share is fair to GreenLight shareholders.
On behalf of GreenLight shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on:

Thursday, May 11, 2023

Autumn, Sustainability reporting, PBC, Farmer, Agriculture, Green-light, Research, RNA, GRNA, Public expenditure, EPA, Sustainability, Health, D, Pharmaceutical industry

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC (Nasdaq: GRNA), a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture, today reported operational highlights and financial results for the first quarter ended March 31, 2023.

Key Points:

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC (Nasdaq: GRNA), a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture, today reported operational highlights and financial results for the first quarter ended March 31, 2023.
“Following regulatory submission of our Varroa mite honeybee solution in the first quarter, we now have two products under EPA review.
Collaboration Revenue: Collaboration revenue was $3.8 million during the first quarter of 2023, compared to no collaboration revenue during the first quarter of 2022.
Net Loss: The Company’s net loss was $28.5 million for the first quarter of 2023, compared to $38.2 million during the first quarter of 2022.

GreenLight Biosciences Releases Inaugural Sustainability Report

Retrieved on:

Wednesday, April 12, 2023

Drug development, Sustainability reporting, Farmer, Agriculture, Crop protection, Green-light, Global health, RNA, GRNA, Plant, Biodiversity, Climate, Health, Food security, Environment, Chief sustainability officer, Pharmaceutical industry

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today released its inaugural Sustainability Report .

Key Points:

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the full potential of RNA to address some of the world’s toughest problems in human health and agriculture, today released its inaugural Sustainability Report .
The report contains the company's sustainability roadmap and includes sustainability updates on its business areas—from developing new tools for farmers that are designed to be targeted, effective, and environmentally responsible to vaccine candidates and potential therapies to improve global health outcomes.
The report highlights seven agriculture products that could reach the market by 2026, subject to applicable regulatory approvals, and three drug development candidates in the human health portfolio.
GreenLight will regularly assess the quality of its sustainability data, focusing on continuous improvements and meeting the expectations of its stakeholders.